Orthofix seeks to understand bone growth technology:
This article was originally published in Clinica
Executive Summary
Orthofix International is funding a trial that will seek to define the molecular and cellular mechanisms of action of its PEMF (pulsed electromagnetic field) technology in stimulating bone growth. The Huntersville, North Carolina firm has given around $2 million to the Orthopaedic Research and Education Foundation as part of a four-year collaboration for the study, which will be conducted at the Cleveland Clinic Foundation, in Ohio. Orthofix plans to expand application of the PEMF platform from bone growth stimulation to other diseases and injuries.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.